Filing Flows › Comparisons › ALEC vs ADMA
Alector vs Adma Biologics: ALEC and ADMA compared
Alector is the larger company: $163M of revenue in its latest quarter (Q3 2026) against $141M for Adma Biologics (Q3 2026). Alector is growing faster (50× against +5% a year earlier). Alector is more profitable, with an operating margin of 76.0% against 48.0%.
Where the money goes: ALEC and ADMA
Alector (ALEC) · Q3 2026
Alector, Q3 2026: revenue $163M (50× year over year), operating margin 76.0%, net earnings $125M, operating cash flow −$24.2M. The chart follows the revenue to costs, profit and cash.
Adma Biologics (ADMA) · Q3 2026
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
| Alector (ALEC) | Adma Biologics (ADMA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $163M | $141M |
| Revenue growth, Y/Y | 50× | +5% |
| Gross margin | — | 70.8% |
| Operating margin | 76.0% | 48.0% |
| Net earnings | $125M | $49.9M |
| Net margin | 76.5% | 35.4% |
| Operating cash flow | −$24.2M | $17.4M |
| Free cash flow | — | $15.4M |
Questions
Which is bigger, Alector or Adma Biologics?
Alector is the larger company: $163M of revenue in its latest quarter (Q3 2026) against $141M for Adma Biologics (Q3 2026).
Is Alector or Adma Biologics growing faster?
Alector is growing faster (50× against +5% a year earlier).
Which is more profitable, Alector or Adma Biologics?
Alector is more profitable, with an operating margin of 76.0% against 48.0%.
More: Alector earnings · how Alector makes money · Adma Biologics earnings · how Adma Biologics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.